$GCTK
GlucoTrack Inc Stock $gctk

$gctk Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000149315224045894 Filed on November 14, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue			$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$1.188M	$531.0K
YoY Change		123.73%	7.27%
% of Gross Profit
Research & Development		$2.063M	$1.693M
YoY Change		21.85%	290.09%
% of Gross Profit
Depreciation & Amortization			$11.00K
YoY Change			120.0%
% of Gross Profit
Operating Expenses		$3.251M	$2.224M
YoY Change		46.18%	139.4%
Operating Profit		-$3.251M	-$2.224M
YoY Change		46.18%	139.4%
Interest Expense		$5.000K	$1.000K
YoY Change		400.0%	-50.0%
% of Operating Profit
Other Income/Expense, Net		$18.00K	$0.00
YoY Change			-100.0%
Pretax Income			-$2.223M
YoY Change			139.55%
Income Tax
% Of Pretax Income
Net Earnings		-$5.087M	-$2.223M
YoY Change		128.83%	139.55%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.91	-$0.10
Diluted Earnings Per Share		-$0.91	-$0.10
COMMON SHARES
Basic Shares Outstanding	5.772M shares	5.478M shares	20.89M shares
Diluted Shares Outstanding		5.595M shares	22.97M shares

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$6.888M
YoY Change		112.53%
Cash & Equivalents	$346.0K	$6.888M
Short-Term Investments
Other Short-Term Assets	$296.0K	$281.0K
YoY Change	5.34%	50.27%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$642.0K	$7.169M
YoY Change	-91.04%	109.13%
LONG-TERM ASSETS
Property, Plant & Equipment	$109.0K	$17.00K
YoY Change	541.18%	-61.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$9.000K
YoY Change		-76.92%
Total Long-Term Assets	$184.0K	$26.00K
YoY Change	607.69%	-68.67%
TOTAL ASSETS
Total Short-Term Assets	$642.0K	$7.169M
Total Long-Term Assets	$184.0K	$26.00K
Total Assets	$826.0K	$7.195M
YoY Change	-88.52%	104.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.857M	$1.249M
YoY Change	48.68%	75.18%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.611M	$1.454M
YoY Change	217.13%	50.67%
LONG-TERM LIABILITIES
Long-Term Debt		$184.0K
YoY Change		-3.66%
Other Long-Term Liabilities	$197.0K	$184.0K
YoY Change	7.07%
Total Long-Term Liabilities	$197.0K	$184.0K
YoY Change	7.07%	-3.66%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.611M	$1.454M
Total Long-Term Liabilities	$197.0K	$184.0K
Total Liabilities	$4.848M	$1.638M
YoY Change	195.97%	41.7%
SHAREHOLDERS EQUITY
Retained Earnings	-$122.4M	-$107.4M
YoY Change	13.88%	6.79%
Common Stock	$118.2M	$113.0M
YoY Change	4.66%	9.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.022M	$5.557M
YoY Change
Total Liabilities & Shareholders Equity	$826.0K	$7.195M
YoY Change	-88.52%	104.93%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	-$5.087M	-$2.223M
YoY Change	128.83%	139.55%
Depreciation, Depletion And Amortization		$11.00K
YoY Change		120.0%
Cash From Operating Activities		-$1.877M
YoY Change		208.72%
INVESTING ACTIVITIES
Capital Expenditures		$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		0.000
YoY Change
NET CHANGE
Cash From Operating Activities		-1.877M
Cash From Investing Activities		0.000
Cash From Financing Activities		0.000
Net Change In Cash		-1.877M
YoY Change		208.72%
FREE CASH FLOW
Cash From Operating Activities		-$1.877M
Capital Expenditures		$0.00
Free Cash Flow		-$1.877M
YoY Change		208.72%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent		usd
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41141
	dei	Entity Registrant Name EntityRegistrantName	GLUCOTRACK, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-0668934
	dei	Entity Address Address Line1 EntityAddressAddressLine1	301 Route 17 North
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 800
	dei	Entity Address City Or Town EntityAddressCityOrTown	Rutherford
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07070
	dei	City Area Code CityAreaCode	(201)
	dei	Local Phone Number LocalPhoneNumber	842-7715
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	GCTK
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	27000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	10000	usd
CY2023Q4	us-gaap	Assets Assets	4905000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	839000	usd
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	376000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	4868000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-80000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1129000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	26000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8991000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5594880	shares
CY2024Q3	GCTK	Earnings Per Share Diluted Including Warrants And Performance Milestones EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones	-0.91
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001506983
CY2023Q4	GCTK	Promissory Notes Current PromissoryNotesCurrent		usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
CY2023Q4	us-gaap	Derivative Liabilities DerivativeLiabilities		usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Marketing Expense MarketingExpense		usd
	us-gaap	Marketing Expense MarketingExpense		usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
	GCTK	Adjustments To Additional Paid In Capital Deemed Dividend Resulted From Trigger Of Down Round Protection Feature Of Certain Warrants Granted AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted		usd
	GCTK	Stock Issued During Period Value Exerciseof Prefunded Warrants Into Shares StockIssuedDuringPeriodValueExerciseofPrefundedWarrantsIntoShares		usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
	GCTK	Stock Issued During Period Value Issuance Of Restricted Shares As Payment For Achievement Of Milestone Pursuant To Purchase Agreement Note4b StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b		usd
	GCTK	Revaluation Expenses Incurred From Settlement Of Financial Liabilities RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities		usd
	GCTK	Revaluation Expenses Related To Derivative Financial Liabilities RevaluationExpensesRelatedToDerivativeFinancialLiabilities		usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
	GCTK	Proceeds From Convertible Debt Private Placement Transaction ProceedsFromConvertibleDebtPrivatePlacementTransaction		usd
	GCTK	Proceeds Received From Underwritten Public Offering ProceedsReceivedFromUnderwrittenPublicOffering		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	GCTK	Deemed Dividend Upon Trigger Of Down Round Protection DeemedDividendUponTriggerOfDownRoundProtection		usd
	us-gaap	Operating Lease Cost OperatingLeaseCost		usd
	GCTK	Issuance Of Shares And Warrants As Settlement Of Financial Liabilities IssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities		usd
CY2024Q3	GCTK	Deemed Dividend Related To Trigger Of Down Round Protection Feature DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature		usd
CY2023Q3	GCTK	Deemed Dividend Related To Trigger Of Down Round Protection Feature DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature		usd
	GCTK	Deemed Dividend Related To Trigger Of Down Round Protection Feature DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature		usd
CY2024Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2023Q4	us-gaap	Derivative Liabilities DerivativeLiabilities		usd
CY2023Q3	GCTK	Discount Amortization And Interest Expenses One DiscountAmortizationAndInterestExpensesOne		usd
	GCTK	Discount Amortization And Interest Expenses One DiscountAmortizationAndInterestExpensesOne		usd
CY2023Q3	us-gaap	Interest Expense InterestExpense		usd
	us-gaap	Interest Expense InterestExpense		usd
CY2023Q3	GCTK	Discount Amortization And Interest Expenses Two DiscountAmortizationAndInterestExpensesTwo		usd
	GCTK	Discount Amortization And Interest Expenses Two DiscountAmortizationAndInterestExpensesTwo		usd
CY2023Q3	GCTK	Revaluation Expenses Related To Derivative Financial Liabilities RevaluationExpensesRelatedToDerivativeFinancialLiabilities		usd
	GCTK	Revaluation Expenses Related To Derivative Financial Liabilities RevaluationExpensesRelatedToDerivativeFinancialLiabilities		usd
CY2023Q3	GCTK	Revaluation Expenses Incurred From Settlement Of Financial Liabilities RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities		usd
	GCTK	Revaluation Expenses Incurred From Settlement Of Financial Liabilities RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities		usd
CY2023Q3	us-gaap	Other Expenses OtherExpenses		usd
	us-gaap	Other Expenses OtherExpenses		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5772026	shares
	dei	Entity Listing Par Value Per Share EntityListingParValuePerShare	0.001
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	346000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4492000	usd
CY2024Q3	us-gaap	Other Assets Current OtherAssetsCurrent	296000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	642000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	65000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	109000	usd
CY2024Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	10000	usd
CY2024Q3	us-gaap	Assets Assets	826000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1857000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	25000	usd
CY2024Q3	GCTK	Promissory Notes Current PromissoryNotesCurrent	1988000	usd
CY2024Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	5000	usd
CY2024Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	37000	usd
CY2024Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	699000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	673000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4611000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1512000	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	197000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	196000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	40000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	4848000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	1708000	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5772026	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5772026	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4178274	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4178274	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2024Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	118223000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	112982000	usd
CY2024Q3	GCTK	Receipts On Account Of Shares ReceiptsOnAccountOfShares	100000	usd
CY2023Q4	GCTK	Receipts On Account Of Shares ReceiptsOnAccountOfShares	48000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	5000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	16000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-122356000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-109853000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-4022000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	3197000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	826000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4905000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2063000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1693000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7800000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2962000	usd
CY2024Q3	us-gaap	Marketing Expense MarketingExpense	125000	usd
	us-gaap	Marketing Expense MarketingExpense	295000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1063000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	531000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2598000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1725000	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	3251000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	2224000	usd
	us-gaap	Operating Expenses OperatingExpenses	10693000	usd
	us-gaap	Operating Expenses OperatingExpenses	4687000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3251000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2224000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10693000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4687000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	12000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	12000	usd
CY2024Q3	GCTK	Finance Income Net FinanceIncomeNet	-1848000	usd
CY2023Q3	GCTK	Finance Income Net FinanceIncomeNet	1000	usd
	GCTK	Finance Income Net FinanceIncomeNet	-1822000	usd
	GCTK	Finance Income Net FinanceIncomeNet	2000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-5087000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2223000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12503000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4685000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-17000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	6000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-11000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	17000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5104000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2217000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12514000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4668000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.91
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.91
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.49
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.49
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.39
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.39
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.38
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.38
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5594880	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5594880	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4593733	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4593733	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5355806	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5355806	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4006527	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4006527	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1230000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4685000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	17000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	260000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8730000	usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	5000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	5557000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	7743000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2223000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	6000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	31000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	5557000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	3197000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12503000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-11000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	239000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	78000	usd
	GCTK	Stock To Be Issued During Period Value Restricted Stock Award Gross StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross	100000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	500000	usd
	GCTK	Stock Issued During Period Value Issuance Of Detachable Warrants Through Private Placement Transactions StockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions	2635000	usd
	GCTK	Stock Issued During Period Value Issuance Of Shares And Warrants As Settlement Of Financial Liabilities StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities	1743000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-4022000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-3289000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-3289000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-5087000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-17000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	11000	usd
CY2024Q3	GCTK	Stock To Be Issued During Period Value Restricted Stock Award Gross StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross	50000	usd
CY2024Q3	GCTK	Stock Issued During Period Value Settlement Of Liabilities With Equity StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity	2567000	usd
CY2024Q3	GCTK	Stock Issued During Period Value Issuance Of Warrant StockIssuedDuringPeriodValueIssuanceOfWarrant	1743000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-4022000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-4022000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12503000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4685000	usd
	us-gaap	Depreciation Depreciation	22000	usd
	us-gaap	Depreciation Depreciation	21000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	239000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	260000	usd
	GCTK	Issuance Of Restricted Shares As Compensation To Board Of Directors IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors	178000	usd
	GCTK	Issuance Of Restricted Shares As Compensation To Board Of Directors IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors	5000	usd
	GCTK	Linkage Difference On Principal Of Loans From Stockholders LinkageDifferenceOnPrincipalOfLoansFromStockholders	1000	usd
	GCTK	Linkage Difference On Principal Of Loans From Stockholders LinkageDifferenceOnPrincipalOfLoansFromStockholders	4000	usd
	GCTK	Revaluation Expenses Incurred From Settlement Of Financial Liabilities RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities	1505000	usd
	GCTK	Revaluation Expenses Related To Derivative Financial Liabilities RevaluationExpensesRelatedToDerivativeFinancialLiabilities	2000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	330000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	216000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	598000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-134000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4147000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	104000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-104000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	500000	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	100000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	360000	usd
	GCTK	Proceeds From Convertible Debt Private Placement Transaction ProceedsFromConvertibleDebtPrivatePlacementTransaction	4000000	usd
	GCTK	Proceeds Received From Underwritten Public Offering ProceedsReceivedFromUnderwrittenPublicOffering	8730000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4960000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8730000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-11000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-17000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4146000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4566000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4502000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2331000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	356000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6897000	usd
	us-gaap	Interest Paid Net InterestPaidNet	37000	usd
	GCTK	Deemed Dividend Upon Trigger Of Down Round Protection DeemedDividendUponTriggerOfDownRoundProtection	855000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	79000	usd
	GCTK	Issuance Of Shares And Warrants As Settlement Of Financial Liabilities IssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities	238000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-122356000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	346000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	8873000	usd
	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable	360000	usd
CY2024Q3	us-gaap	Debt Securities DebtSecurities	30000000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84B_eus-gaap--UseOfEstimates_zRBBoArUAa42" style="margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 21.3pt; text-align: justify; text-indent: -21.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_z7LpEpyqQxfl">Use of Estimates in the Preparation of Financial Statements</span></b></span></td></tr> </table> <p style="margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these interim financial statements, the most significant estimates and assumptions include identification and measurement of financial instruments.</span></td></tr> </table>
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-5087000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2223000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12503000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4685000	usd
	GCTK	Deemed Dividend Related To Trigger Of Down Round Protection Feature DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature	-855000	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5087000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2223000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12503000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5540000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5594880	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4593733	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4593733	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5355806	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5355806	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4006527	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4006527	shares
CY2024Q3	GCTK	Earnings Per Share Diluted Including Warrants And Performance Milestones EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones	-0.91
CY2023Q3	GCTK	Earnings Per Share Diluted Including Warrants And Performance Milestones EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones	-0.49
CY2023Q3	GCTK	Earnings Per Share Diluted Including Warrants And Performance Milestones EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones	-0.49
	GCTK	Earnings Per Share Diluted Including Warrants And Performance Milestones EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones	-2.39
	GCTK	Earnings Per Share Diluted Including Warrants And Performance Milestones EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones	-2.39
	GCTK	Earnings Per Share Diluted Including Warrants And Performance Milestones EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones	-1.38
	GCTK	Earnings Per Share Diluted Including Warrants And Performance Milestones EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones	-1.38
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	718641	shares
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	79000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	65000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	25000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	40000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	73000	usd
CY2024Q3	GCTK	Lessee Operating Lease Liability Imputed Interest LesseeOperatingLeaseLiabilityImputedInterest	-8000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	65000	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y5M1D
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0903	pure
CY2024Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	one-for-five
CY2024Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	300000000	shares
CY2024Q2	us-gaap	Short Term Debt Description ShortTermDebtDescription	The June 27 Notes bear simple interest at a rate of 3% per annum and are due and payable in cash on the earlier of: (a) 12 months from the date of the June 27 Note; or (b) the date the Company raises third-party equity capital in an amount equal to or in excess of $1,000 (the “Maturity Date”). The Company may prepay the June 27 Notes at any time prior to the Maturity Date without penalty. If an event of default occurs, the then-outstanding principal amount of the June 27 Notes plus any unpaid accrued interest will accelerate and become immediately payable in cash.
CY2024Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.95
CY2024Q2	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	15000	usd
CY2024Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	85000	usd
CY2024Q2	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.2865	pure
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	2.45	pure
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0452	pure
CY2024Q3	us-gaap	Debt Default Longterm Debt Description Of Notice Of Default DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault	(i) failure by the Company to pay the July 30 Note balance on the Maturity Date, (ii) the Company becomes subject to a judgement of more than $50,000, (iii) voluntary bankruptcy, or (iv) involuntary bankruptcy. Upon the occurrence of an Event of Default specified in clause (iii) above, the July 30 Note balance shall automatically and immediately become due and payable, in all cases without any action on the part of the July 30 Holder.
CY2024Q3	us-gaap	Debt Default Longterm Debt Amount DebtDefaultLongtermDebtAmount	50000000	usd
CY2024Q3	us-gaap	Debt Instrument Term DebtInstrumentTerm	P10Y
CY2024Q3	GCTK	Embedded Conversion Feature Percentage EmbeddedConversionFeaturePercentage	2	pure
CY2024Q3	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	1450000	usd
CY2024Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2550000	usd
CY2024Q3	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.2865	pure
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.228	pure
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0478	pure
CY2024Q3	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	35000	usd
CY2024Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1415000	usd
	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	35000	usd
	GCTK	Revaluation Expenses Related To Embedded Redemption Feature RevaluationExpensesRelatedToEmbeddedRedemptionFeature	2000	usd
CY2024Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	37000	usd
CY2024Q3	us-gaap	Equity Fair Value Disclosure EquityFairValueDisclosure	238000	usd
CY2024Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	11000	usd
CY2024Q3	us-gaap	Equity Fair Value Disclosure EquityFairValueDisclosure	1505000	usd
CY2024Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	227000	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	20000	shares
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	131000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	30000	shares
CY2024Q3	GCTK	Discount Amortization And Interest Expenses One DiscountAmortizationAndInterestExpensesOne	16000	usd
	GCTK	Discount Amortization And Interest Expenses One DiscountAmortizationAndInterestExpensesOne	16000	usd
CY2024Q3	us-gaap	Interest Expense InterestExpense	5000	usd
	us-gaap	Interest Expense InterestExpense	5000	usd
CY2024Q3	GCTK	Discount Amortization And Interest Expenses Two DiscountAmortizationAndInterestExpensesTwo	309000	usd
	GCTK	Discount Amortization And Interest Expenses Two DiscountAmortizationAndInterestExpensesTwo	309000	usd
CY2024Q3	GCTK	Revaluation Expenses Related To Derivative Financial Liabilities RevaluationExpensesRelatedToDerivativeFinancialLiabilities	2000	usd
	GCTK	Revaluation Expenses Related To Derivative Financial Liabilities RevaluationExpensesRelatedToDerivativeFinancialLiabilities	2000	usd
CY2024Q3	GCTK	Revaluation Expenses Incurred From Settlement Of Financial Liabilities RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities	1505000	usd
	GCTK	Revaluation Expenses Incurred From Settlement Of Financial Liabilities RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities	1505000	usd
CY2024Q3	us-gaap	Interest Expense Deposits InterestExpenseDeposits	-7000	usd
CY2023Q3	us-gaap	Interest Expense Deposits InterestExpenseDeposits	-1000	usd
	us-gaap	Interest Expense Deposits InterestExpenseDeposits	-38000	usd
	us-gaap	Interest Expense Deposits InterestExpenseDeposits	-2000	usd
CY2024Q3	us-gaap	Other Expenses OtherExpenses	18000	usd
	us-gaap	Other Expenses OtherExpenses	23000	usd
CY2024Q3	GCTK	Finance Income Net FinanceIncomeNet	-1848000	usd
CY2023Q3	GCTK	Finance Income Net FinanceIncomeNet	1000	usd
	GCTK	Finance Income Net FinanceIncomeNet	-1822000	usd
	GCTK	Finance Income Net FinanceIncomeNet	2000	usd

Files In Submission

Name	View Source	Status
gctk-20240930_def.xml	Edgar Link	unprocessable
0001493152-24-045894-index-headers.html	Edgar Link	pending
0001493152-24-045894-index.html	Edgar Link	pending
0001493152-24-045894.txt	Edgar Link	pending
0001493152-24-045894-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
gctk-20240930.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
gctk-20240930_cal.xml	Edgar Link	unprocessable
gctk-20240930_lab.xml	Edgar Link	unprocessable
gctk-20240930_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GCTK
GlucoTrack Inc Stock $gctk

2024 Q4 Form 10-Q Financial Statement

#000149315224045894 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GCTK GlucoTrack Inc Stock $gctk

2024 Q4 Form 10-Q Financial Statement

#000149315224045894 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GCTK
GlucoTrack Inc Stock $gctk